Skip to content
Drugs Monitor

Drugs Monitor

Tracking drugs for COVID19

Click for Menu
  • Navigate
  • Contact Us
  • Navigate
  • Contact Us
  • (30 Sep 2020) Tocilizumab & Corticosteroid- Better outcomes in older patients with severe COVID

    October 1, 2020

    Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: a single-center retrospective study https://www.medrxiv.org/content/10.1101/2020.09.26.20202283v1 A retrospective single center study including consecutive patients older than 65 years that developed severe COVID19 between March 3 and May 1,… Continue reading "(30 Sep 2020) Tocilizumab & Corticosteroid- Better outcomes in older patients with severe COVID"

  • (28 Sep 2020) Corticosteroids- may not be beneficial for patients with mild COVID-19

    October 1, 2020

    Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study https://doi.org/10.1007/s40121-020-00337-y Of 82 patients with a mild infection, 40 patients were male (48.8%), with a median age of 49 years (interquartile… Continue reading "(28 Sep 2020) Corticosteroids- may not be beneficial for patients with mild COVID-19"

  • (27 Sep 2020) Tocilizumab- associated with a lower risk of death or ICU or death in patients with higher CRP levels

    September 29, 2020

    Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A multicenter cohort study https://doi.org/10.1016/j.cmi.2020.09.021 A total of 1,229 patients were analyzed, with 261 patients (61 deaths) in the tocilizumab group and 969 patients (120 deaths) in the control group.… Continue reading "(27 Sep 2020) Tocilizumab- associated with a lower risk of death or ICU or death in patients with higher CRP levels"

  • (25 Sep 2020) Corticosteroids- less mortality in severe patients compared to critical patients

    September 26, 2020

    Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicenter study. https://doi.org/10.1016/j.cmi.2020.09.014 Of 1717 patients with COVID-19 evaluated, 513 patients were included in the study; of these 170 (33%) were treated with corticosteroids. During the hospitalization 166 (34%)… Continue reading "(25 Sep 2020) Corticosteroids- less mortality in severe patients compared to critical patients"

  • (23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters

    September 26, 2020

    The effects of favipiravir on hematological parameters of covid-19 patients. https://doi.org/10.1590/1806-9282.66.S2.65 Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. The mean age of the patients receiving treatment with favipiravir was 63.7+/-12.3… Continue reading "(23 Sep 2020) Favipiravir- suppression in the erythrocyte series, no adverse effects in other hematologic parameters"

  • (23 Sep 2020) Tinospora Cordifolia- proven to be effective in asymptomatic patients

    September 26, 2020

    Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 infection: An Open Label Feasibility Study https://www.medrxiv.org/content/10.1101/2020.09.20.20198515v1 An open label, feasibility trial (NCT04542876)was conducted on 46 patients in the hospital setting. A single-arm study with no control… Continue reading "(23 Sep 2020) Tinospora Cordifolia- proven to be effective in asymptomatic patients"

  • (21 Sep 2020) Hydroxychloroquine- Pre-exposure prophylaxis with HCQ did not significantly reduce laboratory-confirmed Covid-19

    September 22, 2020

    Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial https://www.medrxiv.org/content/10.1101/2020.09.18.20197327v1 A randomized, double-blind, placebo-controlled clinical trial (NCT04328467) of healthcare workers with ongoing exposure to persons with Covid-19 was conducted. Participants across the United States and in the… Continue reading "(21 Sep 2020) Hydroxychloroquine- Pre-exposure prophylaxis with HCQ did not significantly reduce laboratory-confirmed Covid-19"

  • (18 Sep 2020) Corticosteroids- not beneficial at later stage in old population

    September 19, 2020

    Association between corticosteroids and intubation or death among patients with COVID-19 pneumonia in non-ICU settings: an observational study using of real-world data from 51 hospitals in France and Luxembourg https://www.medrxiv.org/content/10.1101/2020.09.16.20195750v1 Among the 891 patients included in the analysis, 203 were… Continue reading "(18 Sep 2020) Corticosteroids- not beneficial at later stage in old population"

  • (15 Sep 2020) Hydroxychloroquine & Azithromycin- associated with reduced in-hospital mortality in patients

    September 17, 2020

    Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID-19 patients https://doi.org/10.1111/cts.12860 A retrospective single-center cohort study including 377 consecutive patients admitted for pneumonia related to coronavirus disease (COVID-19) was conducted. Of these 297 were in combination treatment,… Continue reading "(15 Sep 2020) Hydroxychloroquine & Azithromycin- associated with reduced in-hospital mortality in patients"

  • (14 Sep 2020) Heparin- associated with a clinically significant improvement in a-line patency duration

    September 17, 2020

    A low dose heparinized saline protocol is associated with improved duration of arterial line patency in critically ill COVID-19 patients https://doi.org/10.1016/j.jcrc.2020.08.025 In this observational cohort study, patients >/=18 years with COVID-19 admitted to an ICU at one institution from March… Continue reading "(14 Sep 2020) Heparin- associated with a clinically significant improvement in a-line patency duration"

Posts navigation

Older Posts
Newer Posts

Copyright © 2025 Drugs Monitor. All Rights Reserved. Theme by ilovewp